Detection of platelet antibodies by anti-kappa light chain facilitation of C-FDA (KC-FDA) thrombocytotoxicity.
Sensitivity of the carboxyfluorescein diacetate (C-FDA) thrombocytotoxicity technique for the detection of antiplatelet antibodies has been enhanced by the addition of an anti-Kappa light chain antibody facilitation step. This new technique, KC-FDA, was compared with the platelet suspension immunofluorescence test (PSIFT) by titering platelet-reactive allo-anti-PlAl and anti-HLA antibodies. The results show that compared to PSIFT, KC-FDA is more sensitive for detecting platelet specific antibodies (PlAl), is more or equally sensitive for detecting other antibodies (HLA), and is significantly faster and easier to perform.
D000906:Antibodies / Q000032:analysis*; D001792:Blood Platelets / Q000276:immunology*; D005260:Female; D005452:Fluoresceins; D005455:Fluorescent Antibody Technique; D006801:Humans; D007147:Immunoglobulin Light Chains / Q000276:immunology*; D007145:Immunoglobulin kappa-Chains / Q000276:immunology*; D007223:Infant; D008297:Male; D008722:Methods
D000906:Antibodies; D005452:Fluoresceins; D007147:Immunoglobulin Light Chains; D007145:Immunoglobulin kappa-Chains; C027780:carboxyfluoresceindiacetate